Every second, our FDA-cleared AI-based ecosystem compares 20+ physiological signals* from a wearable biosensor with data from millions of other chronic patients. The result? Powerful pattern recognition designed to help clinicians predict and prevent deterioration before it happens.
Every second, our FDA-cleared AI-based ecosystem compares 20+ physiological signals* from a wearable biosensor with data from millions of other chronic patients. The result? Powerful pattern recognition that helps predict and prevent deterioration before it happens.
What if patients suffering from heart failure, COPD, chronic pain, or cancer could spend less time in hospitals and more time feeling confident and cared for at home? What if networks, clinicians, and payers could turn fewer readmissions into a higher level of care for all? And what if drug companies could more dramatically demonstrate, in real-time, the physiological impact and value of pharmacotherapy candidates?
At Biofourmis, we use patient physiology data and advanced analytics to turn those "what-ifs" into "ah-has" for some of the world's most respected healthcare providers and pharmaceutical companies—collaborators like Novartis, Chugai, Brigham and Women's Hospital, and Mayo Clinic that use our clinically validated, predictive platform to more precisely manage, intervene, and treat chronic patients in a way that's proactive and liberating. That's the power of personally predictive care.Get To Know Us
Our Biovitals® platform collects and interprets vast amounts of population metadata and compares it to real-time patient physiological signals to provide a clearer picture of chronic patients and their disease trajectory—a real-time picture designed to help clinicians predict and prevent serious medical events. Its actionable insights powered by machine learning, deep neural networks, and a clinical-grade Everion® wearable.See How Biovitals® Works
Biovitals® delivers actionable information by bringing disease, data, machine-learning, and clinical-grade hardware together in one customizable ecosystem. Learn how we can tailor Biovitals® to improve real-world outcomes for the unique needs of health systems, payers and pharmaceutical companies.
Around the world and across multiple collaborations and studies, our Biovitals® Platform is helping clinical teams see patients like never before.
Circulation, AHA Journal
This RCT demonstrated that an algorithm-drive, navigator-administered medication optimization program enhanced implementation of GDMT compared with usual care in patients with HFrEF. The data supports remote titration using our Biovitals® Treatment algorithms for personalized, sequential, stepped titration of guideline-directed heart failure medication therapies.
Annals of Internal Medicine
This RCT demonstrated substitutive home hospitalization reduced cost, healthcare use, and readmissions while increasing physical activity compared with usual hospital care. Patients were monitored using wearable biosensor patch and machine-based algorithms, which produced alarms for review by both nurse and physicians.
This study demonstrated the ability of our FDA-cleared Biovitals® Analytics Engine to detect subtle physiology changes precursor to decompensation in patients with chronic condition. The data validates its unique features – device and disease agnostic platform for continuous physiology monitoring.
arXive.org – Cornell University
The study demonstrates the capability of our FDA-cleared RhythmAnalytics® platform to detect >15 types of cardiac arrhythmias using continuous ECG recordings. The overall performance of RhythmAnalytics® outperformed a panel of cardiologists and other industry leading detection models
Oncology – International Journal of Cancer Research and Treatment
The study demonstrated strong feasibility and patients’ acceptance of remote monitoring using Everion® and companion app in palliative cancer patients. 83% of patients completed the whole study by wearing the Everion® biosensor and 73% used the companion app to complete daily digital questionnaires (pain and distress scale)
IISE Transactions on Occupational Ergonomics and Human Factors
The study investigated the wearing comfort of nine devices for monitoring physiology and physical activity in soldiers. Results concluded Everion® achieved the highest score associated with wearing comfort and acceptability during day-to-day military training. This study was a collaboration between Switzerland, Netherlands, United States of America and United Kingdom through NATO Panel HFM- 260.
We're proud to collaborate with some of the world's most respected healthcare organizations, research hospitals, and biopharma companies. Together, we're improving patient outcomes, advancing clinical research, reducing healthcare costs, and accelerating drug research and development.
Let's get you up to speed.
BOSTON, Sept. 3, 2020 /PRNewswire/ -- Biofourmis, a fast-growing global leader in digital therapeutics that powers personalized predictive care, has announced the completion of a $100 million Series C financing round led by SoftBank Vision Fund 2, with participation by existing investors Openspace Ventures, MassMutual Ventures, Sequoia Capital and EDBI.
September 3, 2020
Unnecessary patient hospital stays are not only a drain on hospitals’ resources, but also a risk for other patients.
Telehealth can reduce unnecessary patient stays by transferring non-acute patients to their homes, where they can continue receiving appropriate care.
For instance, Biofourmis‘ AI-based remote patient monitoring technology allows stabilized cardiac patients to continue to be cared for at home. Its wearable armband monitors patient vitals 24/7, detects cardiac abnormalities, and alerts clinicians on potential intervention measures.
August 24, 2020
BOSTON, [U.S.] AND SINGAPORE, July 29 and 30, 2020 – Biofourmis, a global leader in digital therapeutics that powers personalized predictive care, announced today that its Biovitals® Sentinel platform has been deployed by the Ministry of Health (MOH) in Singapore to remotely monitor COVID-19-positive patients to aid in early detection of deterioration and to enable clinicians and nurse teams to intervene early.
July 29, 2020
TOKYO and BOSTON, July 21, 2020 /PRNewswire/ -- and July 22, 2020 - Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) and Biofourmis, a Boston-based digital therapeutics company, announced that they have partnered to develop a digital solution for the objective assessment of pain associated with endometriosis.
July 21, 2020
We're helping some of the most respected names in healthcare deliver measurably better outcomes. Let us show you what personally predictive care can do for your organization.Contact Us